Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Whitlock

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Plos One|August 13, 2013
The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysisGitanjali M Singh, Goodarz Danaei, Farshad Farzadfar, et al.
Lancet (London, England)|March 15, 2011
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies, David Wormser, Stephen Kaptoge, et al.
The Lancet. HIV|July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.
The Lancet. Infectious Diseases|July 5, 2022
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysisNicolò Girometti, Ruth Byrne, Margherita Bracchi, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapyMohammed Altaf, Carla Nel, Timothy Tipoe, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO TrialMing Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV|May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trialMing J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Plos One|August 13, 2013
The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysisGitanjali M Singh, Goodarz Danaei, Farshad Farzadfar, et al.
Lancet (London, England)|March 15, 2011
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies, David Wormser, Stephen Kaptoge, et al.
The Lancet. HIV|July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.
The Lancet. Infectious Diseases|July 5, 2022
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysisNicolò Girometti, Ruth Byrne, Margherita Bracchi, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapyMohammed Altaf, Carla Nel, Timothy Tipoe, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO TrialMing Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV|May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trialMing J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
Pageof 8